Clinically, this suggests that combining ferroptosis inducers with mTOR or HIF2α inhibitors-and potentially targeting PLIN2-could provide a multifaceted therapeutic strategy against advanced ccRCC. The gene discussed is PLIN2; the disease is nonpapillary renal cell carcinoma.